Low dose aspirin and age-related macular degeneration: randomised controlled trial

小剂量阿司匹林与年龄相关性黄斑变性：随机对照试验

• 批准号: nhmrc : 1051625
• 负责人: A/Pr Robyn Woods
• 金额: $ 69.56万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/low-dose-aspirin-controlled-trial/112228
• 关键词: Low; dose; aspirin; age; related

Age-related macular degeneration (AMD) is a major cause of visual impairment in advanced countries, responsible for nearly half of all legal blindness in Australia. Due to increased life expectancy, the number of people with this progressive late onset disease will double by 2025. Aspirin could prevent or delay the onset of AMD in older persons but its bleeding risk also needs to be considered. This project will determine whether treatment with low dose aspirin reduces incidence or progression of AMD.

在发达国家，老年性黄斑变性（AMD）是造成视力损害的主要原因，澳大利亚法定失明的近一半是由老年性黄斑变性造成的。由于预期寿命延长，到2025年，患有这种进行性晚发性疾病的人数将增加一倍。阿司匹林可以预防或延缓老年人AMD的发病，但其出血风险也需要考虑。该项目将确定低剂量阿司匹林治疗是否能减少AMD的发病率或进展。